2 completed. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow ASLAN Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) Varlitinib, mFOLFOX6, Placebo - Gastric Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 52 | 2017-08-31 | 2022-02-15 |
| Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine, Placebo (for Varlitinib) - Biliary Tract Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 151 | 2017-07-04 | 2021-08-03 |
Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Gallbladder Neoplasms (1) · Neoplasms (1) · Stomach Neoplasms (1)
ARRY-334543 (2) · Capecitabine (1)
Hong Kong (2) · Singapore (2) · South Korea (2) · Taiwan (2) · Australia (1) · China (1) · Estonia (1) · Hungary (1) · Japan (1) · Lithuania (1) · Malaysia (1) · Poland (1) · Spain (1) · Thailand (1) · United States (1)